OGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.52B

-4.4%

0.741

-17.72%

1.52B

+0.15%

1.006

-1.34%

1.56B

-2.37%

1.066

+6.63%

Estimates Revision

The market is revising Downward the revenue expectations for Organon & Co. (OGN) for FY2025, with the revenue forecasts being adjusted by -0.87% over the past three months. During the same period, the stock price has changed by -16.15%.

Revenue Estimates for FY2025

Revise Downward

-0.87%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.12%

In Past 3 Month

Stock Price

Go Down

-16.15%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast OGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGN is 8.75 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

3 Sell

Moderate Sell

Current: 0.000

Low

5.00

Averages

8.75

High

12.00

Current: 0.000

Low

5.00

Averages

8.75

High

12.00

Barclays

Underweight

initiated

$7.50

2025-12-08

Reason

Barclays

Price Target

$7.50

2025-12-08

initiated

Underweight

Reason

Barclays initiated coverage of Organon with an Underweight rating and $7.50 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."

Morgan Stanley

Terence Flynn

Equal Weight

downgrade

$10 -> $9

2025-11-11

Reason

Morgan Stanley

Terence Flynn

Price Target

$10 -> $9

2025-11-11

downgrade

Equal Weight

Reason

Morgan Stanley analyst Terence Flynn lowered the firm's price target on Organon to $9 from $10 and keeps an Equal Weight rating on the shares. The company, which announced that it had identified and ceased the improper sales practices that resulted in recent personnel changes and concluded that improper practices were limited to Nexplanon, lowered revenue guidance to $6.2B-$6.25B from $6.275B-$6.375B, predominantly driven by U.S. policy headwinds for Nexplanon and challenges in the respiratory business, the analyst tells investors.

JPMorgan

Underweight

downgrade

$14 -> $12

2025-11-11

Reason

JPMorgan

Price Target

$14 -> $12

2025-11-11

downgrade

Underweight

Reason

JPMorgan lowered the firm's price target on Organon to $12 from $14 and keeps an Underweight rating on the shares. The firm reduced estimates citing Nexplanon and respiratory headwinds post the earnings report.

Piper Sandler

Overweight -> Underweight

downgrade

$18 -> $5

2025-10-27

Reason

Piper Sandler

Price Target

$18 -> $5

2025-10-27

downgrade

Overweight -> Underweight

Reason

Piper Sandler downgraded Organon to Underweight from Overweight with a price target of $5, down from $18.

Piper Sandler

David Amsellem

Overweight -> Underweight

downgrade

$18 -> $5

2025-10-27

Reason

Piper Sandler

David Amsellem

Price Target

$18 -> $5

2025-10-27

downgrade

Overweight -> Underweight

Reason

As previously reported, Piper Sandler analyst David Amsellem downgraded Organon to Underweight from Overweight with a price target of $5, down from $18, calling the investigation that uncovered Nexplanon-related channel stuffing that led to the resignation of CEO Kevin Ali an "egregious breakdown in internal controls." The firm believes that it will likely take "quite some time" for the board and new senior leadership to build "any modicum of credibility," even if it becomes clear that there were no other instances of lapses in internal controls and no other instances of malfeasance, the analyst tells investors.

Piper Sandler

David Amsellem

Overweight

downgrade

$24 -> $18

2025-05-15

Reason

Piper Sandler

David Amsellem

Price Target

$24 -> $18

2025-05-15

downgrade

Overweight

Reason

Piper Sandler analyst David Amsellem lowered the firm's price target on Organon to $18 from $24 and keeps an Overweight rating on the shares after hosting an investor luncheon with Organon senior management. The firm says that not surprisingly, a key topic of discussion was the dividend cut and focus on accelerating deleveraging. Piper notes that "it is certainly not lost on us" that Organon's shares have taken its lumps in the wake of the decision, and beyond that, the shares are down about 57% since the company announced the acquisition of Dermavant last September. Investors are clearly unhappy. The firm's take is a bit different. Specifically, wrestling net debt/EBITDA down to the 3-times, coupled with driving visibility into long-term EBITDA stability at a minimum gives the company the best shot at sustaining a richer multiple, it argues.

Valuation Metrics

The current forward P/E ratio for Organon & Co (OGN.N) is 1.88, compared to its 5-year average forward P/E of 4.77. For a more detailed relative valuation and DCF analysis to assess Organon & Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

4.77

Current PE

1.88

Overvalued PE

6.25

Undervalued PE

3.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

6.59

Current EV/EBITDA

5.17

Overvalued EV/EBITDA

7.72

Undervalued EV/EBITDA

5.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.90

Current PS

0.31

Overvalued PS

1.25

Undervalued PS

0.54

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

OGN News & Events

Events Timeline

No data

News

7.5

01-08Businesswire

Organon Partners with Daiichi Sankyo to Commercialize Nilemdo® in Northern Europe

5.0

01-06Yahoo Finance

Stagwell Appoints Wendy Lund as Global CEO to Accelerate Healthcare Growth

8.0

2025-12-16NASDAQ.COM

Strategy to Increase OGN Yield to 9.8% Through Options

People Also Watch

Frequently Asked Questions

What is Organon & Co (OGN) stock price today?

The current price of OGN is 8.05 USD — it has decreased -0.98 % in the last trading day.

What is Organon & Co (OGN)'s business?

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

What is the price predicton of OGN Stock?

What is Organon & Co (OGN)'s revenue for the last quarter?

Organon & Co revenue for the last quarter amounts to 1.60B USD, increased 1.26 % YoY.

What is Organon & Co (OGN)'s earnings per share (EPS) for the last quarter?

Organon & Co. EPS for the last quarter amounts to 0.61 USD, decreased -55.80 % YoY.

What changes have occurred in the market's expectations for Organon & Co (OGN)'s fundamentals?

How many employees does Organon & Co (OGN). have?

Organon & Co (OGN) has 10000 emplpoyees as of January 10 2026.

What is Organon & Co (OGN) market cap?

Today OGN has the market capitalization of 2.09B USD.